Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan
Condition: Type2 Diabetes Interventions: Drug: Insulin Degludec U100; Drug: Insulin Glargine Sponsors: Weill Cornell Medical College in Qatar; Novo Nordisk A/S Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Endocrinology | Insulin | Lantus | Middle East Health | Qatar Health | Research | Study